Centro De Inmunologia Molecular

Lena Aguiar García

Luis Enrique Fernández Molina

Circe Mesa Pardillo

Audry Fernández Gómez

Maura Lisett Rábade Chediak

Lourdes Hernández De La Rosa

Vladimir Peña Sánchez

Liliana Oliver Ríos

Camilo Rodríguez Rodríguez

Leslie Pérez Ruíz

Anet Valdés Zayas

María Caridad Rubio Hernández

Idelmis Curbelo Haredia

Rydell Alvarez Arzola

Elias Antonio Gracia Medina

Orlando Valdés Guerrero

The present invention describes a pharmaceutical composition whose active ingredient includes conjugates of membrane vesicles ofand the GM3 ganglioside in a conjugation ratio in excess of proteins, has particular characteristics of size, surface charge and a morphology associated with nano-particulate systems that give it advantageous properties as an immunomodulator, because it induces a convenient and significant reduction of myeloid-derived suppressor cells that has an impact on the response of lymphocytes and on the survival of patients with tumors. The invention further discloses the use of the pharmaceutical composition disclosed in the treatment of cancer, particularly those cancers where the myeloid-derived suppressor cells (MDSCs) are high; as well as a method of treatment with said composition in cancer patients and a method to select those who will receive said treatment.

Ganglioside GM3-containing nanoparticles as immunomodulators

Growing community of inventors

Prov. Artemisa, Cuba

Lena Aguiar García